2509 Qyuns Therapeutics Co., Ltd. HKEX · China

Qyuns Therapeutics Co. (2509) news

Qyuns Therapeutics Co., Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 2509, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Qyuns Therapeutics Co. news

We have not published a story on Qyuns Therapeutics Co. yet. When there is news, it will appear here.

Questions about Qyuns Therapeutics Co.

What is the ticker symbol of Qyuns Therapeutics Co.?

Qyuns Therapeutics Co., Ltd. trades under the ticker 2509 on HKEX.

Where is Qyuns Therapeutics Co. listed?

Qyuns Therapeutics Co., Ltd. is listed on HKEX.

Which country or territory is Qyuns Therapeutics Co. listed under?

Our directory records Qyuns Therapeutics Co., Ltd. under China.

What does Qyuns Therapeutics Co. do?

Our directory classifies Qyuns Therapeutics Co., Ltd. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Qyuns Therapeutics Co.?

The ISIN recorded for Qyuns Therapeutics Co., Ltd. is CNE1000069W9.

Does aibio.space cover Qyuns Therapeutics Co.?

aibio.space lists Qyuns Therapeutics Co., Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Qyuns Therapeutics Co.?

Companies in our directory listed in the same country and business area as Qyuns Therapeutics Co.: TransThera Sciences (Nanjing)., Shanghai Obio Technology (Group) Corp., Medtide, Hanx Biopharmaceuticals (Wuhan) Co., Beijing Tiantan Biological Products Corporation, Pacific Shuanglin Bio-pharmacy Co..

Investor discussion: Qyuns Therapeutics Co.

Members talk about Qyuns Therapeutics Co. (2509). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Qyuns Therapeutics Co., newest first. Each line links the filing it comes from.

Jun 26, 2026Mergers
Transaction under the Listing Rules: DISCLOSEABLE AND CONNECTED TRANSACTION IN RELATION TO THE ACQUISITION OF EQUITY INTERESTS IN A SUBSIDIARY. Source
May 8, 2026Financings
Share or debt issue: CIRCULAR FOR ANNUAL GENERAL MEETING. Source
Apr 29, 2026Mergers
Transaction under the Listing Rules: DISCLOSEABLE TRANSACTIONS IN RELATION TO SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS. Source
Mar 23, 2026Mergers
Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION IN RELATION TO SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCT. Source
Aug 25, 2025Financings
Share or debt issue: COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE. Source
Aug 17, 2025Financings
Share or debt issue: PLACING OF NEW H SHARES UNDER GENERAL MANDATE. Source
Jul 4, 2025Mergers
Transaction under the Listing Rules: DISCLOSEABLE TRANSACTIONS IN RELATION TO SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS. Source
Apr 29, 2025Financings
Share or debt issue: CIRCULAR FOR ANNUAL GENERAL MEETING. Source
Mar 7, 2025Mergers
Transaction under the Listing Rules: DISCLOSEABLE TRANSACTIONS IN RELATION TO SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS. Source
Nov 22, 2024Mergers
Transaction under the Listing Rules: DISCLOSEABLE TRANSACTIONS IN RELATION TO SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS. Source

Press releases

Headlines of Qyuns Therapeutics Co.'s own announcements, newest first. Each opens the full release on the newswire that carried it.

Oct 26, 2026HKEXnews
ANNOUNCEMENT BOOK CLOSURE PERIOD FOR EXTRAORDINARY GENERAL MEETING
Oct 2, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT PHASE III CLINICAL STUDY RESULTS OF OTURKIBART (QX005N) FOR TREATMENT OF PRURIGO NODULARIS PRESENTED AS A LATE-BREAKING ORAL PRESENTATION AT EADV 2026
Sep 22, 2026HKEXnews
CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE REVISION OF ANNUAL CAPS FOR THE QX001S FRAMEWORK AGREEMENT; AND RESIGNATION AND PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR
Aug 19, 2026HKEXnews
UNAUDITED INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026
Jul 31, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT QX027N OBTAINS TWO CLINICAL TRIAL APPROVALS FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
Jul 29, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT IN RELATION TO CONCURRENT $278 MILLION PRIVATE PLACEMENT AND PROPOSED NASDAQ CAPITAL MARKET LISTING OF THE COMPANY'S PARTNER CALDERA THERAPEUTICS
Jun 26, 2026HKEXnews
DISCLOSEABLE AND CONNECTED TRANSACTION IN RELATION TO THE ACQUISITION OF EQUITY INTERESTS IN A SUBSIDIARY
Jun 9, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT ON-MARKET SHARE REPURCHASE UNDER THE REPURCHASE MANDATE
May 29, 2026HKEXnews
ARTICLES OF ASSOCIATION
May 29, 2026HKEXnews
(1) POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 29, 2026; AND (2) DISSOLUTION OF THE SUPERVISORY COMMITTEE AND RESIGNATION OF SUPERVISORS
May 27, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT MILESTONE PAYMENT RECEIVED FROM ROCHE FOR THE FIRST PARTICIPANT DOSED IN PHASE I CLINICAL TRIAL OF QX031N
May 21, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT APPROVALS OF MARKETING AUTHORISATION APPLICATION AND SUPPLEMENTAL APPLICATION FOR QX001S (USTEKINUMAB INJECTION) FOR USE IN CROHN'S DISEASE
May 8, 2026HKEXnews
Documents on Display
May 8, 2026HKEXnews
NOTICE OF 2025 ANNUAL GENERAL MEETING
May 8, 2026HKEXnews
CIRCULAR FOR ANNUAL GENERAL MEETING
Apr 29, 2026HKEXnews
DISCLOSEABLE TRANSACTIONS IN RELATION TO SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS
Mar 27, 2026HKEXnews
Terms of Reference of the Nomination Committee
Mar 27, 2026HKEXnews
Terms of Reference of the Remuneration and Appraisal Committee
Mar 27, 2026HKEXnews
Terms of Reference of the Audit Committee
Mar 27, 2026HKEXnews
Terms of Reference of the Strategy and Development Committee

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:2509 on TradingView.

Listing details

Company: Qyuns Therapeutics Co., Ltd.
Ticker: 2509
Listing: HKEX
Country or territory: China
Business scope: Biotechnology
ISIN: CNE1000069W9
Last quote in directory: 2026-10-22
Directory source: Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction